Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BioCardia Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BCDA
Nasdaq
8731
https://www.biocardia.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BioCardia Inc
Insiders Are Buying These 11 Penny Stocks
- Apr 2nd, 2024 9:41 pm
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 6:30 pm
BioCardia Full Year 2023 Earnings: Misses Expectations
- Mar 29th, 2024 10:11 am
Q4 2023 BioCardia Inc Earnings Call
- Mar 28th, 2024 9:58 am
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
- Mar 27th, 2024 8:00 pm
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
- Mar 20th, 2024 11:00 am
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
- Mar 13th, 2024 11:00 am
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
- Mar 12th, 2024 11:00 am
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
- Mar 4th, 2024 1:00 pm
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
- Feb 8th, 2024 12:00 pm
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
- Jan 31st, 2024 12:00 pm
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
- Jan 3rd, 2024 12:00 pm
Positive Signs As Multiple Insiders Buy BioCardia Stock
- Jan 1st, 2024 7:33 pm
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
- Dec 19th, 2023 12:00 pm
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
- Dec 18th, 2023 12:16 pm
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
- Nov 29th, 2023 12:00 pm
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
- Nov 16th, 2023 5:56 pm
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
- Nov 15th, 2023 4:04 pm
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
- Nov 14th, 2023 12:15 pm
BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 5:48 pm
Scroll